Subscribe
istock-669281432_nataliaderiabina
NataliaDeriabina / iStockphoto.com
22 November 2017Europe

Prenatal test infringes Illumina patents, rules English High Court

A prenatal test sold by molecular diagnostics company Premaitha Health infringes patents owned by genetic sequencing firm Illumina, a UK court has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.

More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB